A change from calcineurin inhibitors to mammalian target of rapamycin inhibitor-based regimens is an option with possible beneficial effects on tumor recurrence and overall survival; however, the number of calcineurin inhibitors is still limited; thus, this therapy is still not a routine option [10,24,25,26]. The gene discussed is MTOR; the disease is neoplasm.